Andrew Kramar

6.7k total citations
102 papers, 4.6k citations indexed

About

Andrew Kramar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Andrew Kramar has authored 102 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 20 papers in Surgery. Recurrent topics in Andrew Kramar's work include Statistical Methods in Clinical Trials (16 papers), Breast Cancer Treatment Studies (12 papers) and Testicular diseases and treatments (10 papers). Andrew Kramar is often cited by papers focused on Statistical Methods in Clinical Trials (16 papers), Breast Cancer Treatment Studies (12 papers) and Testicular diseases and treatments (10 papers). Andrew Kramar collaborates with scholars based in France, United States and Belgium. Andrew Kramar's co-authors include Caroline Mollévi, Joëlle Simony-Lafontaine, Catherine Hill, Monique G. Lê, Éric Lartigau, T. Lacornerie, Jean Grenier, Marc Ychou, Alain Lortholary and Stéphane Culine and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Andrew Kramar

102 papers receiving 4.5k citations

Peers

Countries citing papers authored by Andrew Kramar

Since Specialization

Citations

This map shows the geographic impact of Andrew Kramar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Kramar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Kramar more than expected).

Fields of papers citing papers by Andrew Kramar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Kramar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Kramar. The network helps show where Andrew Kramar may publish in the future.

Co-authorship network of co-authors of Andrew Kramar

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Kramar. A scholar is included among the top collaborators of Andrew Kramar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Kramar. Andrew Kramar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study 2015 ·European Journal of Cancer ·Xavier Pivot, Thomas Suter, J.-M. Nabholtz, Jean‐Yves Pierga, Marc Espié, Alain Lortholary, David Khayat, Iris Pauporté, Gilles Romieu, Andrew Kramar, P. Fumoleau	49
2	Primary tumor delineation based on 18FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy 2015 ·Radiotherapy and Oncology ·Mathieu Leclerc, Éric Lartigau, T. Lacornerie, Jean‐François Daisne, Andrew Kramar, Vincent Grégoire	49
3	Novel Technique for Hepatic Fiducial Marker Placement for Stereotactic Body Radiation Therapy 2014 ·International Journal of Radiation OncologyBiologyPhysics ·H. Jarraya, (unknown), Emmanuelle Tresch, F. Bonodeau, T. Lacornerie, X. Mirabel, Thomas Boulanger, S. Taïeb, Andrew Kramar, Éric Lartigau, L. Ceugnart	14
4	CSF CA 15-3 in breast cancer-related leptomeningeal metastases 2014 ·Journal of Neuro-Oncology ·Émilie Le Rhun, Andrew Kramar, (unknown), Marie Girot, (unknown), Audrey Mailliez, Fahed Zaïri, (unknown), Y Robin, Sophie Taillibert, François Dubois, Jacques Bonneterre, Marc C. Chamberlain	15
5	6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial 2013 ·The Lancet Oncology ·X. Pivot, Gilles Romieu, Marc Debled, Jean‐Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, P. Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, María Rios, Sophie Abadie‐Lacourtoisie, N. Tubiana-Mathieu, Laurent Cany, Stéphanie Catala, David Khayat, Iris Pauporté, Andrew Kramar	211
6	Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial 2012 ·Journal of Clinical Oncology ·Anja Lorch, (unknown), Andrew Kramar, Christian Kollmannsberger, Jörg T. Hartmann, Carsten Bokemeyer, Oliver Rick, J. Beyer	66
7	Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy 2012 ·Radiation Oncology ·S. Dewas, Jean‐Emmanuel Bibault, X. Mirabel, I. Fumagalli, Andrew Kramar, H. Jarraya, T. Lacornerie, (unknown), Éric Lartigau	55
8	A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases 2012 ·Radiation Oncology ·I. Fumagalli, Jean‐Emmanuel Bibault, S. Dewas, Andrew Kramar, X. Mirabel, B. Prévost, T. Lacornerie, (unknown), Éric Lartigau	38
9	Life-expectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models 2012 ·Critical Reviews in Oncology/Hematology ·(unknown), David Olmos, Charles Ferté, Philippe A. Cassier, Andrew Kramar, Alain Duhamel, Nicolas Penel	19
10	Designing group sequential randomized clinical trials with time to event end points using a R function 2012 ·Computer Methods and Programs in Biomedicine ·Thomas Filleron, Jocelyn Gal, Andrew Kramar	3
11	Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility Study 2012 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Andrew Kramar, (unknown), S. Dewas, Bernard Coche‐Dequeant, M. Degardin, Jean‐Louis Lefebvre, T. Lacornerie, Éric Lartigau	81
12	Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up 2012 ·Bulletin du Cancer ·Thomas Filleron, Andrew Kramar, Florence Dalenc, M. Spielmann, P. Fumoleau, Pierre Kerbrat, Anne‐Laure Martin, Henri Roché	2
13	Multidimensionality of microarrays: Statistical challenges and (im)possible solutions 2011 ·Molecular Oncology ·Stefan Michiels, Andrew Kramar, Serge Koscielny	13
14	An R function to non-parametric and piecewise analysis of competing risks survival data 2010 ·Computer Methods and Programs in Biomedicine ·Thomas Filleron, Agnès Laplanche, Jean‐Marie Boher, Andrew Kramar	16
15	Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women 2009 ·Clinical Cancer Research ·Caroline Desmetz, Caroline Mollévi, Philippe Rochaix, Pierre‐Jean Lamy, Andrew Kramar, Philippe Rouanet, Thierry Maudelondé, Alain Mangé, Jérôme Solassol	87
16	Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP 2008 ·Journal of Clinical Oncology ·Stéphane Culine, Andrew Kramar, Christine Théodore, L. Geoffrois, Christine Chevreau, Pierre Biron, Binh Bui Nguyen, Jean‐François Héron, Pierre Kerbrat, Armelle Caty, R. Delva, P. Fargeot, Karim Fizazi, Jeannine Bouzy, Jean‐Pierre Droz	59
17	Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas 2008 ·European Journal of Cancer ·V. Granci, Frédéric Bibeau, Andrew Kramar, Florence Boissière‐Michot, Simon Thézenas, (unknown), Céline Gongora, Pierre Martineau, Maguy Del Rio, Marc Ychou	22
18	A comparison of early effects with two dose rates in brachytherapy of cervix carcinoma in a prospective randomised trial 1994 ·European Journal of Cancer ·Philippe Lambin, A. Gerbaulet, Andrew Kramar, Pierre Scalliet, Christine Haie-Méder, Guy Michel, (unknown), Jeannine Bouzy, Edmond P. Malaise, D. Chassagne	12
19	Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumours 1993 ·European Journal of Cancer ·Jean-Pierre Droz, Andrew Kramar, (unknown)	21
20	Platinum‐based combination chemotherapy in advanced non‐small cell lung cancer: A randomized phase II trial of the cancer and leukemia group B 1990 ·Medical and Pediatric Oncology ·Mark R. Green, Andrew Kramar, Richard L. Schilsky, (unknown), Bonnie Zimmer, Frederick Richards, Arthur T. Skarin, James R. Anderson	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact